Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer

NCT03941730 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03941730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03941730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 28, 2019
Completion date
December 31, 2026
Enrollment
8 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced triple-negative breast carcinoma, anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, metastatic triple-negative breast carcinoma, recurrent breast carcinoma